Published Studies Related to Biltricide (Praziquantel)
A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. [2011.06]
CONCLUSION: A higher dose of 60 mg/kg of praziquantel offers no significant efficacy advantage over standard 40 mg/kg for treating intestinal schistosomiasis caused by either S. mansoni or S. japonicum. The results of this study support WHO recommendation and should be used to inform policy decisions in the countries.
Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. [2011.04]
AIM: This study investigated the kinetic disposition, metabolism and enantioselectivity of albendazole (ABZ) and praziquantel (PZQ) administered alone and in combination to healthy volunteers... CONCLUSIONS: The pharmacokinetic interaction between ABZ and PZQ in healthy volunteers was demonstrated by the observation of increased plasma concentrations of ASON, both ASOX enantiomers and (-)-(R)-PZQ. Clinically, the combination of ABZ and PZQ may improve the therapeutic efficacy as a consequence of higher concentration of both active drugs. On the other hand, the magnitude of this elevation may represent an increased risk of side effects, requiring, certainly, reduction of the dosage. However, further studies are necessary to evaluate the efficacy and safety of this combination. (c) 2011 The Authors. British Journal of Clinical Pharmacology (c) 2011 The British Pharmacological Society.
A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. [2011.04]
Integrated chemotherapy of neglected tropical diseases (NTD) through mass drug administration given as a single dose would increase treatment coverage and cost-effectiveness...
Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial. [2011.02]
BACKGROUND: Praziquantel is the only drug available for treatment of Opisthorchis viverrini, although in-vivo studies point to activity of mefloquine, artesunate, and tribendimidine against this liver fluke. We aimed to assess the efficacy and safety of these drugs compared with that of praziquantel in patients with O viverrini infection... INTERPRETATION: Tribendimidine seems to be at least as efficacious as the drug of choice, praziquantel, for the treatment of O viverrini infections; both drugs were well tolerated. Mefloquine, artesunate, and mefloquine-artesunate did not show an effect. Tribendimidine should be further investigated with large clinical trials. FUNDING: Swiss National Science Foundation, University of Basel. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Field trial of praziquantel for control of fishborne zoonotic trematodes in reservoir hosts in Vietnam. [2010.12.15]
This field trial was conducted to determine whether 40 or 75 mg/kg of praziquantel is suitable for treatment of fishborne zoonotic trematodes (FZT) in naturally infected dogs (n=10) and cats (n=11). Three days after treatment all animals at either dose were negative for small trematode eggs...
Clinical Trials Related to Biltricide (Praziquantel)
Praziquantel-Pharmacokinetic Study [Recruiting]
The purpose of the study is to understand whether the drug praziquantel (PZQ) is metabolized
or broken down differently when women are pregnant versus not pregnant. PZQ is used to treat
schistosomiasis (worm infection). Researchers will study how PZQ is broken down among 15
women who are 12-16 weeks pregnant, 15 women who are 30-36 weeks pregnant, and 15 women
nonpregnant women who are producing breast milk. All women will be 18 or older and otherwise
healthy. The usual practice is to wait until after mothers have finished pregnancy and
breast feeding before giving PZQ. Participants will receive 2 doses of PZQ separated by 3
hours. Study procedures will include a 24 hour hospital stay following administration of
PZQ, blood, stool and urine samples, ultrasound if pregnant, and physical exams of mother
and baby. Patient participation for mother/infant pair is about 9 months.
Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis [Recruiting]
Liver fibrosis is the most serious complication of schistosomiasis mansoni. However only
limited proportion of subjects with infection develop this pathology and there is limited
knowledge on risk factors for the differential morbidity patterns observed in endemic
communities. Our preliminary cross-sectional study indicated that serum levels of
antioxidants may be related with the development of fibrosis. The present project is a
randomised double blinded placebo controlled prospective study investigating the role of
food based antioxidant supplements on the outcome of anti-schistosomal chemotherapy with
regards to the extent of fibrosis reversal.
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes [Not yet recruiting]
In this study, it is hypothesized that helminth infections modulate immune responses against
HIV-1 infection resulting into increased HIV-1 multiplication, faster progression to AIDS
and increased episodes of AIDS-related opportunistic infections. Furthermore, the effect of
helminth infections on progression of HIV-1 infection is dependent on helminth infection
intensity, host background immunity, nutritional status, demographic factors and
socio-economic status. Also, treatment of helminth infections using praziquantel and
albendazole among HIV-1 infected individuals will lead to reduction in HIV-1 viral loads,
improvement of CD4+ counts, CD4+/CD8+ ratio and Hb levels, improved weight gain and
reduction of episodes of HIV-1 related opportunistic infections. In addition, HIV-1
infection is associated with poor anthelminthic treatment outcome as compared to non-HIV
Safety and Efficacy of Mirazid for Schistosomiasis Treatment [Recruiting]
Clinical Trial Phase: Phase III
- Compare Mirazid and Praziquantel cure rates for both Schistosoma species.
- Compare Mirazid and Praziquantel effect in lowering the intensity of infection for both
Secondary Objective: Identify and compare the types and severity of side and adverse effects
between the Mirazid and Praziquantel.
Study Population: 200 Schistosomiasis infected persons of both types of Schistosomiasis aged
from 15-35 years. Those subjects will be selected from among those screened. Subjects will
include both genders excluding chronically ill such as chronic liver disease patients and
those with both types of Schistosomiasis.
Recruitment Period: 3 months and subjects follow up for another 3 months followed by 3 months
for statistical analysis and report writing Study Duration: Total study duration is expected
to be 9 months: 3 months for recruitment, 3 months for follow up and 3 months for data
management and report writing.
Endpoints: Will be measured at 3 months of successful administration of treatment either
Mirazid or Praziquantel as per the randomization scheme. By then, final assessment of the
response to treatment will be done by examining urine or stool of the subject for presence
of Schistosoma eggs and its density if found.
Three negative urine or stool samples collected 2-days apart at 12 weeks post treatment will
indicate treatment success. One positive sample collected at week 12 will indicate infection
Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil [Completed]
The primary objective of this project is to evaluate the efficacy and safety of praziquantel
60 mg/kg in the treatment of schistosomiasis, as compared to the standard 40 mg/kg therapy in
a representative community from a highly endemic area of schistosomiasis in Northeastern
Brazil. Cure rates, reduction in egg counts and proportions of reported side-effects in
children at the 10-19 y age-range with at least 100 eggs per gram of faeces will be compared
between regimens, aiming to evaluate the superiority of 60 mg/kg over the 40mg/kg dose
currently recommended by the WHO. Reinfection rates will also be evaluated aiming to improve
transmission control within the local health system, including re-treatment combined with
auxiliary control measures. Features related to the clinical, nutritional and immunological
status of the patients prior to treatment will also be investigated in association with the
outcome of praziquantel treatment.
Reports of Suspected Biltricide (Praziquantel) Side Effects
Abdominal Pain (2),
Cytolytic Hepatitis (2),
Drug Ineffective (1),
Angioedema (1), more >>